OAC
CRVS icon

OMERS Administration Corp’s Corvus Pharmaceuticals CRVS Stock Holding History

OMERS Administration Corp’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-82,300
Closed -$262K – 916
2025
Q1 		$262K Buy
82,300
+6,800
+9% +$32K ﹤0.01% 887
2024
Q4 		$404K Buy
+75,500
New +$564K ﹤0.01% 750

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OMERS Administration Corp's CRVS Position: Q2 2025 in Review

OMERS Administration Corp sold out of Corvus Pharmaceuticals (CRVS) in Q2 2025, closing a stake of 82,300 shares — an estimated $262K sold.

OMERS Administration Corp first reported a position in CRVS in Q4 2024 and held it in 2 quarters. The position peaked at $404K in Q4 2024. 92 funds tracked by Wall St. Rank hold CRVS as of Q2 2025.

  • OMERS Administration Corp reported no remaining Corvus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • OMERS Administration Corp sold 82,300 Corvus Pharmaceuticals shares in Q2 2025, an estimated $262K.
  • OMERS Administration Corp first reported a position in Corvus Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • OMERS Administration Corp's Corvus Pharmaceuticals position peaked at $404K in Q4 2024.
  • 92 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2025.

Based on OMERS Administration Corp's 13F filing for Q2 2025, filed 13 Aug 2025.